Literature DB >> 18406701

Partially autonomous cortisol secretion by incidentally discovered adrenal adenomas.

H Lavoie1, A Lacroix.   

Abstract

Recent studies of the function of adrenal "incidentalomas" have revealed that a proportion of those tumors secrete cortisol insufficiently to produce overt clinical Cushing s syndrome, but that their autonomous cortisol production can suppress the hypothalamo-pituitaryadrenal (HPA) axis to various degrees; this needs to be recognized to avoid acute adrenal insufficiency after adrenalectomy. Several diagnostic approaches have been utilized to identify the partially autonomous cortisol-secreting adenomas. It has been suggested that a lack of normal suppression of cortisol (> 140 nmol/L) on the morning after 1-mg oral dexamethasone at bedtime would identify most functional autonomous cortisol-secreting tumors. Based on this criterion, approximately 18% of published cases of incidentalomas would secrete cortisol autonomously. However, other tests indicating alterations of the HPA axis, such as abnormal adrenal iodocholesterol uptake or decreased plasma levels of dehydroepiandrosterone sulfate (DHAS), were found to be present in up to 79%-86% of incidentalomas. This is illustrated by the description of three patients with incidentalomas with plasma cortisol levels < 140 nmol/L in 2 of 3 patients after 1-mg dexamethasone overnight; however, various degrees of HPA axis suppression were demonstrated by an i.v. dexamethasone (4-mg) suppression test, decreased plasma DHAS levels and unilateral adrenal iodocholesterol uptake. After laparoscopic adrenalectomy, the response of plasma cortisol to 250 mug i.v. of ACTH (1-24) was subnormal in 2 of 3 patients and was restored to normal within 2 months. We conclude that the criterion of a plasma cortisol level > 140 nmol/L, after an overnight 1-mg dexamethasone suppression test, underestimates the incidence of partially autonomous cortisol-secreting adrenal adenomas. The literature on this subject is reviewed, and recommendations for evaluation and treatment are presented.

Entities:  

Year:  1995        PMID: 18406701     DOI: 10.1016/1043-2760(95)00091-u

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  4 in total

Review 1.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 2.  The clinical evaluation of silent adrenal masses.

Authors:  B Ambrosi; E Passini; T Re; L Barbetta
Journal:  J Endocrinol Invest       Date:  1997-02       Impact factor: 4.256

Review 3.  Subclinical Cushing's syndrome.

Authors:  Massimo Terzolo; Giuseppe Reimondo; Silvia Bovio; Alberto Angeli
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas.

Authors:  G Reimondo; B Allasino; S Bovio; L Saba; A Ardito; A Angeli; M Terzolo
Journal:  J Endocrinol Invest       Date:  2010-07-13       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.